MedMatrix Rx
Daily 340B Morning Briefing for Executives
The legal landscape for the 340B program remains active with significant developments. Froedtert Memorial Lutheran Hospital has filed a lawsuit against CVS Health over alleged 340B diversion worth $18 million. The American Hospital Association is pushing back against CMS’s proposed 340B payment cuts and clawbacks, urging the agency to reconsider its 2027 outpatient payment rule. NASP has submitted comments on CMS’s proposed changes to 340B payment methodologies. These developments highlight ongoing tensions and negotiations surrounding the 340B program.
EXECUTIVE SUMMARY
01
Froedtert Hospital sues CVS for $18M in alleged 340B diversion.
Froedtert Memorial Lutheran Hospital filed a lawsuit against CVS Health, alleging $18 million in 340B savings diversion.
Froedtert Memorial Lutheran Hospital filed a lawsuit against CVS Health, alleging $18 million in 340B savings diversion.
Source: Becker’s Hospital Review
02
AHA urges CMS to reconsider 2027 340B payment cuts.
AHA has called on CMS to withdraw proposed 340B payment cuts and clawbacks in its 2027 outpatient payment rule.
AHA has called on CMS to withdraw proposed 340B payment cuts and clawbacks in its 2027 outpatient payment rule.
Source: Becker’s Hospital Review
03
NASP comments on CMS’s 340B payment changes.
NASP submitted comments to CMS on proposed changes to Medicare reimbursement for 340B-acquired drugs under CY 2027 HOPPS.
NASP submitted comments to CMS on proposed changes to Medicare reimbursement for 340B-acquired drugs under CY 2027 HOPPS.
Source: NASP
04
Court decertifies 11 clinics in 340B dispute.
A federal judge ordered the decertification of 11 clinics from the 340B program for not meeting statutory requirements.
A federal judge ordered the decertification of 11 clinics from the 340B program for not meeting statutory requirements.
Source: Becker’s Hospital Review
05
Hospital groups oppose CMS’s 2027 outpatient rule.
AHA, AAMC, and AMGA urged CMS to reconsider provisions in its 2027 outpatient rule, including 340B payment cuts.
AHA, AAMC, and AMGA urged CMS to reconsider provisions in its 2027 outpatient rule, including 340B payment cuts.
Source: Becker’s Hospital Review
06
Court updates in 340B legal battles.
Recent court updates include interventions in AbbVie’s 340B lawsuit and ongoing disputes over contract pharmacy access.
Recent court updates include interventions in AbbVie’s 340B lawsuit and ongoing disputes over contract pharmacy access.
Source: Becker’s Hospital Review
07
HRSA’s 340B Rebate Model Pilot Program to launch January 2027.
HRSA’s revised 340B Rebate Model Pilot Program will launch in January 2027, focusing on MFP drugs.
HRSA’s revised 340B Rebate Model Pilot Program will launch in January 2027, focusing on MFP drugs.
Source: Drug Channels
08
AHA pushes for upfront Medicare drug pricing.
AHA urges CMS to require upfront negotiated Medicare drug prices instead of retrospective rebates in its proposed rule.
AHA urges CMS to require upfront negotiated Medicare drug prices instead of retrospective rebates in its proposed rule.
Source: Becker’s Hospital Review
09
AAMC and AHA seek changes in 340B provisions.
AAMC and AHA filed comments targeting changes in CMS’s Medicare Drug Price Negotiation Program rule and 340B legislation.
AAMC and AHA filed comments targeting changes in CMS’s Medicare Drug Price Negotiation Program rule and 340B legislation.
Source: Becker’s Hospital Review
10
Specialty pharmacy trends indicate rising utilization.
The 2026 specialty pharmacy trend report shows increasing costs driven by rising use, with biosimilars impacting pricing.
The 2026 specialty pharmacy trend report shows increasing costs driven by rising use, with biosimilars impacting pricing.
Source: Drug Channels
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing legal and regulatory challenges surrounding the 340B program reflect the complexity and contentious nature of drug pricing and reimbursement in the healthcare sector. Multiple stakeholders, including hospitals, pharmaceutical companies, and government agencies, are involved in these disputes. The outcomes will significantly impact the financial and operational strategies of healthcare providers and pharmacies. The pushback against CMS’s proposed rules and the legal battles over 340B eligibility and pricing show the need for careful compliance with requirements and planning to mitigate potential financial risks.
Emerging risks.
- Legal disputes over 340B eligibility and pricing could lead to financial losses for hospitals and clinics.
- CMS’s proposed 340B payment cuts may increase financial pressure on hospitals, affecting patient care services.
- Decertification of clinics from the 340B program could disrupt drug access for vulnerable populations.
- The shift towards a rebate model could complicate reimbursement processes for 340B entities.
Emerging opportunities.
- Hospitals can advocate for policy changes that better align with their financial and operational goals.
- Engaging in public comments and advocacy can influence CMS’s final rulemaking on 340B payments.
- Participating in pilot programs like the HRSA 340B Rebate Model can provide insights into future reimbursement models.
- Using biosimilars and negotiated drug pricing can help reduce drug costs and improve access.
Key actions for providers.
- Monitor ongoing litigation and regulatory changes to anticipate impacts on 340B program participation.
- Engage with industry associations to stay informed and contribute to advocacy efforts on 340B issues.
- Evaluate financial strategies to mitigate potential impacts from CMS’s proposed 340B payment cuts.
- Consider participating in HRSA’s 340B Rebate Model Pilot Program to understand its implications on reimbursement.
TOP STORIES
Froedtert Hospital sues CVS for $18M in alleged 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert Memorial Lutheran Hospital alleges CVS diverted $18 million in 340B savings.
- The lawsuit names CVS Health, CaremarkPCS Health, and WellPartner as defendants.
- The complaint was filed in the U.S. District Court for the Eastern District of Wisconsin.
AHA urges CMS to reconsider 2027 340B payment cuts.
Becker’s Hospital Review · August 26, 2026
- AHA opposes CMS’s plan to increase 340B repayment rates to 3%.
- The proposed rule would accelerate a Medicare payment clawback.
- Over 500 hospitals could face repayments exceeding $1 million annually.
Court decertifies 11 clinics in 340B dispute.
Becker’s Hospital Review · August 20, 2026
- A federal judge decertified 11 clinics from the 340B program.
- The decision was based on failure to meet statutory funding requirements.
- Amgen and Genentech were among the drugmakers granted summary judgment.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
NASP comments on CMS’s 340B payment changes.
NASP · September 1, 2026
- NASP submitted comments on CMS’s CY 2027 HOPPS proposed rule.
- Focus on Medicare reimbursement changes for 340B-acquired drugs.
- Comments address operational and compliance considerations for specialty pharmacies.
Hospital groups oppose CMS’s 2027 outpatient rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA submitted comments against the 2027 outpatient rule.
- Groups oppose 340B payment cuts and site-neutral payment expansion.
- The comment period for the proposed rule closed on August 31, 2026.
AHA pushes for upfront Medicare drug pricing.
Becker’s Hospital Review · August 18, 2026
- AHA urges CMS to require upfront negotiated Medicare drug prices.
- The proposal targets retrospective rebates in CMS’s proposed rule.
- AHA filed comments on August 17, 2026.
340B PROGRAM DEVELOPMENTS
HRSA’s 340B Rebate Model Pilot Program to launch January 2027.
Drug Channels · August 25, 2026
- HRSA announced a revised 340B Rebate Model Pilot Program.
- The pilot will launch on January 1, 2027, focusing on MFP drugs.
- The program addresses nonduplication requirements under the Inflation Reduction Act.
STATE DEVELOPMENTS
Washington — 340B Program Participation and Medicaid Carve-In Requirements
Washington State Health Care Authority · September 7, 2026
- Washington State’s Health Care Authority outlines requirements for 340B-covered entities participating in the Medicaid Drug Rebate Program (MDRP).
- Entities must decide whether to carve-in (use 340B drugs for Medicaid clients) or carve-out (purchase drugs outside the 340B program).
- To carve-in, entities must inform HRSA and ensure their Medicaid provider number is listed in HRSA’s Medicaid Exclusion File to prevent duplicate discounts.
- The state does not support 340B contract pharmacies and requires that drugs purchased under 340B be billed directly by the covered entities.
- Source: Washington State Health Care Authority
- Date: September 7, 2026
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
| D.D.C. | COREWELL HEALTH WILLIAM BEAUMONT UNIVERSITY HOSPITAL v. KENNEDY [source] | September 3, 2026 |
| D. Maryland | State of New York v. U.S. Department of Health and Human Services [source] | August 27, 2026 |
| D.D.C. | ABBVIE INC. v. KENNEDY, 1:26-cv-1190-RDM, filed 2026-08-24. [source] | August 24, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
Identified and summarized recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from various organizations and platforms.
AHA Comments on Cassidy 340B Discussion Draft Legislation
American Hospital Association (AHA) · August 25, 2026
- Main theme: AHA provides feedback on proposed 340B program changes.
- Stakeholder sentiment: AHA expresses concern, stating the draft “would fundamentally alter the operation of the program.”
- Potential implications: Potential challenges in maintaining access to affordable medications for patients.
- Credibility: AHA is a reputable organization representing hospitals and health systems.
340B Health Responds to Senator Cassidy’s 340B Discussion Draft
340B Health · June 25, 2026
- Main theme: 340B Health responds to proposed 340B program changes.
- Stakeholder sentiment: 340B Health expresses concern, stating the draft “would profoundly alter 340B and make it more difficult for safety-net hospitals.”
- Potential implications: Potential reduction in support for safety-net hospitals serving underserved communities.
- Credibility: 340B Health is a national trade association representing 340B hospitals.
WHAT TO WATCH NEXT
- Monitor the outcome of Froedtert’s lawsuit against CVS for potential impacts on 340B program practices. [source]
- Watch for CMS’s final decision on the 2027 outpatient payment rule and its implications for 340B payments. [source]
- Track developments in the HRSA 340B Rebate Model Pilot Program set to launch in January 2027. [source]
- Follow the legal proceedings in the COREWELL HEALTH v. KENNEDY case for its potential impact on 340B regulations. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.